The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
Read More

Related News:

1. FDA approves Sutent for rare type of pancreatic cancer
2. FDA approves Inlyta to treat patients with a type of advanced kidney cancer
3. FDA approves new test to help determine if breast cancer patients are candidates for Herceptin treatment
4. NIH study finds experimental drug benefits patients with rare type of cancer
5. FDA approves new treatment for rare type of pancreatic cancer